Rola stresu oksydacyjnego w patogenezie orbitopatii Gravesa
References
- Abraham-Nordling M., Byström K., Törring O., Lantz M., Berg G., Calissendorff J., Nyström H.F., Jansson S., Jörneskog G., Karlsson F.A., Nyström E., Ohrling H., Orn T., Hallengren B., Wallin G.: Incidence of hyperthyroidism in Sweden. Eur. J. Endocrinol., 2011; 165: 899–905
- Akarsu E., Buyukhatipoglu H., Aktaran S., Kurtul N.: Effects of pulse methyloprednisolone and oral methyloprednisolone treatments on serum levels of oxidative stress markers in Graves’ ophthalmopathy. Clin. Endocrinol., 2011; 74: 118–124
- Ames B.N., Cathcart R., Schwiers E., Hochstein P.: Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci. USA, 1981; 78: 6858–6862
- Azizi F., Raiszadeh F., Solati M., Etemadi A., Rahmani M., Arabi M.: Serum paraoxonase 1 activity is decreased in thyroid dysfunction. J. Endocrinol. Invest., 2003; 26: 703–709
- Barnes P.J.: Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin. Sci., 1998; 94: 557–572
- Bartalena L., Baldeschi L., Boboridis K., Eckstein A., Kahaly G.J., Marcocci C., Perros P., Salvi M., Wiersinga W.M., European Group on Graves’ Orbitopathy (EUGOGO): The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J., 2016; 5: 9–26
- Bartalena L., Piantanida E.: Cigarette smoking: Number one enemy for Graves’ ophthalmopathy. Pol. Arch. Med. Wewn., 2016; 126: 725–726
- Bartalena L., Tanda M.L.: Clinical practice. Graves’ ophthalmopathy. N. Engl. J. Med., 2009; 360: 994–1001
- Bartelena L., Tanda M.L., Piantanida E., Lai A.: Oxidative stress Graves’ ophthalmopathy: In vitro studies and therapeutic implications. Biofactors, 2003; 19: 155–163
- Başkol G., Dolbun Seçkin K., Bayram F., Tanriverdi F.: Investigation of serum paraoxonase -1 activity and lipid levels in patients with hyperthyroidism. Turk. J. Med. Sci., 2012; 42: 1166–1171
- Bednarek J., Wysocki H., Sowiński J.: Oxidative stress peripheral parameters in Graves’ disease: The effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin. Biochem., 2005; 38: 13–18
- Bednarek J., Wysocki H., Sowiński J.: Peripheral parameters of oxidative stress in patients with infiltrative Graves’ ophtalmopathy treated with corticosteroids. Immunol. Lett., 2004; 93: 227–232
- Bednarek J., Wysocki H., Sowinski J.: Oxidation products and antioxidant markers in plasma of patients with Graves’ disease and toxic multinodular goiter: Effect of methimazole treatment. Free Radic. Res., 2004; 38: 659–664
- Bianchi G., Solaroli E., Zaccheroni V., Grossi G., Bargossi A.M., Melchionda N., Marchesini G.: Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: Effect of treatment. Horm. Metab. Res., 1999; 31: 620–624
- Blair I.A.: Lipid hydroperoxide-mediated DNA damage. Exp. Gerontol., 2001; 36: 1473–1481
- Botta R., Lisi S., Marcocci C., Sellari-Franceschini S., Rocchi R., Latrofa F., Menconi F., Altea M.A., Leo M., Sisti E., Casini G., Nardi M., Pinchera A., Vitti P., Marinò M.: Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts. Thyroid, 2013; 23: 92–96
- Bouzas E.A., Karadimas P, Mastorakos G., Koutras D.A.: Anti-oxidant agents in the treatment of Graves’ opthalmopathy. Am. J. Ophthalmol., 2000; 129: 618–622
- Burch H.B., Lahiri S., Bahn R.S., Barnes S.: Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp. Eye Res., 1997; 65: 311–316
- Cawood T.J., Moriarty P., O’Farrelly C., O’Shea D.: Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J. Clin. Endocrinol. Metab., 2007; 92: 59–64
- Choi W., Li Y., Ji Y.S., Yoon K.C.: Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score. BMC Ophthalmol., 2018; 18: 303
- Dong Y.H., Fu D.G.: Autoimmune thyroid disease: Mechanism, genetics and current knowledge. Eur. Rev. Med. Pharmacol. Sci., 2014; 18: 3611–3618
- Duntas L.H.: Selenium and the thyroid: A close-knit connection. J. Clin. Endocrinol. Metab., 2010; 95: 5180–5188
- Effraimidis G., Wiersinga W.M.: Mechanisms in endocrinology: Autoimmune thyroid disease: Old and new players. Eur. J. Endocrinol., 2014; 170: R241–R252
- Gianoukakis A.G., Khadavi N., Smith T.J.: Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid, 2008; 18: 953–958
- Haddad J.J.: Oxygen sensing and oxidant/redox-related pathways. Biochem. Biophys. Res. Commun., 2004; 316: 969–977
- Halliwell B., Gulleridge J.M.: Oxygen radicals and the nervous system. Trends Neurosci., 1985; 8: 22–26
- Hardeland R., Pandi-Perumal S.R., Cardinali D.P.: Melatonin. Int. J. Biochem. Cell. Biol., 2006; 38: 313–316
- Heufelder A.E., Wenzel B.E., Bahn R.S.: Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts. J. Clin. Endocrinol. Metab., 1992; 74: 737–742
- Heufelder A.E., Wenzel B.E., Bahn R.S.: Cell surface localization of a 72 kilodalton heat shock protein in retroocular fibroblasts from patients with Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab., 1992; 74: 732–736
- Hondur A., Konuk O., Dincel A.S., Bilgihan A., Unal M., Hasanreisoglu B.: Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy. Curr. Eye Res., 2008; 33: 421–427
- Iyer S., Bahn R.: Immunopathogenesis of Graves’ ophthalmopathy: The role of the TSH receptor. Best. Pract. Res. Clin. Endocrinol. Metab., 2012; 26: 281–289
- Karasek D., Cibickova L., Karhanova M., Kalitova J., Schovanek J., Frysak Z.: Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab. Endokrynol. Pol., 2017; 68: 498–504
- Karbownik M., Lewinski A.: The role of oxidative stress in physiological and pathological processes in the thyroid gland; possible involvement in pineal-thyroid interactions. Neuro Endocrinol. Lett., 2003; 24: 293–303
- Karihtala P., Kauppila S., Puistola U., Jukkola-Vuorinen A.: Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology, 2011; 58: 854–862
- Khalilzadeh O., Anvari M., Momen-Heravi F., Esteghamati A., Rashidi A., Mahmoudi M., Nikbin B., Amirzargar A.: Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves’ disease. Clin. Exp. Med., 2010; 10: 123–128
- Khong J.J., McNab A.A., Ebeling P.R., Craig J.E., Selva D.: Pathogenesis of thyroid eye disease: Review and update on molecular mechanisms. Br. J. Ophthalmol., 2016; 100: 142–150
- Komosinska-Vassev K., Olczyk K., Kucharz E.J., Marcisz C., Winsz-Szczotka K., Kotulska A.: Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy. Clin. Chim. Acta, 2000; 300: 107–117
- Kucharzewski M., Braziewicz J., Majewska U., Góźdź S.: Concentration of selenium in the whole blood and the thyroid tissue of patients with various thyroid diseases. Biol. Trace Elem. Res., 2002; 88: 25–30
- Laurberg P., Berman D.C., Bülow Pedersen I., Andersen S., Carlé A.: Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J. Clin. Endocrinol. Metab., 2012; 97: 2325–2332
- Levine M.: New concepts in the biology and biochemistry of ascorbic acid. N. Engl. J. Med., 1986; 314: 892–902
- Lindquist S.: The heat-shock response. Ann. Rev. Biochem., 1986; 55: 1151–1191
- Lisi S., Botta R., Lemmi M., Sellari-Franceschini S., Altea M.A., Sisti E., Casini G., Nardi M., Marcocci C., Pinchera A., Marinò M.: Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J. Endocrinol. Invest., 2011; 34: 521–527
- Liu X., Zhang J., Meng Z., Jia Q., Tan J., Zhang G., Li X., Liu N., Hu T., Zhou P., Zhang Q., Song K., Jia Q.: Gender impact on the correlations between Graves’ hyperthyroidism and hyperuricemia in Chinese. Ir. J. Med. Sci., 2019; 188: 843–848
- Marcocci C., Altea M.A., Kahaly G., Pitz S., Krassas G., Boboridia K., Bartalena L., Sivelli M., von Arx G., Stahl M., Nardi M., Mourits M., Baldeschi L., Pinchera A., Wiersinga W. I wsp.: Selenium and pentoxifylline in patients with mild Graves’ orbitopathy: Results of a randomized placebo-controlled double-blind clinical trial. Endocr. Abstr., 2010; 22: P866
- Marcocci C., Bartalena L.: Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy. J. Endocrinol. Investig., 2013; 36: 15–20
- Marcocci C., Kahaly G.J., Krassas G.E., Bartalena L., Prummel M., Stahl M., Altea M.A., Nardi M., Pitz S., Boboridis K., Sivelli P., von Arx G., Mourits M.P., Baldeschi L., Bencivelli W. i wsp.: Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med., 2011; 364: 1920–1931
- Marinò M., Chiovato L., Lisi S., Altea M.A., Marcocci C., Pinchera A.: Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: The hypothesis of Kriss revisited. J. Endocrinol. Invest., 2004; 27: 230–236
- Marnett L.J.: Oxy radicals, lipid peroxidation and DNA damage. Toxicology, 2002; 181–182: 219–222
- Mayer L., Romić Z., Skreb F., Bacić-Vrca V., Cepelak I., Zanić-Grubisić T., Kirin M.: Antioxidants in patients with hyperthyroidism. Clin. Chem. Lab. Med., 2004; 42: 154–158
- Mezosi E., Szabo J., Nagy E.V., Borbely A., Varga E., Paragh G., Varga Z.: Nongenomic effect of thyroid hormone on free-radical production in human polymorphonuclear leukocytes. J. Endcorinol., 2005; 185: 121–129
- Mikozami T., Salvi M., Wall J.R.: Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? J. Endocrinol. Invest., 2004; 27: 221–229
- Murrell G.A., Francis M.J., Bromley L.: Modulation of fibro-blast proliferation by oxygen free radicals. Biochem. J., 1990; 265: 659–665
- Myśliwiec J., Palyga I., Nikolajuk A., Kowalska A., Gorska M.: Serum interleukin-16 and RANTES during treatment of Graves’ orbitopathy with corticosteroids and teleradiotherapy. Endokrynol. Pol., 2012; 63: 92–96
- Niedernhofer L.J., Daniels J.S., Rouzer C.A., Greene R.E., Marnett L.J.: Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J. Biol. Chem., 2003; 278: 31426–31433
- Nowak M., Marek B., Karpe J., Kos-Kudła B., Siemińska L., Kajdaniuk D., Treszer T.: Serum concentration of VEGF and PDGF-AA in patients with active thyroid orbitopathy before and after immunosuppressive therapy. Exp. Clin. Endocrinol. Diabetes, 2014; 122: 582–586
- Nowak M., Siemińska L., Karpe J., Marek B., Kos-Kudła B., Kajdaniuk D.: Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy. J. Endocrinol. Invest., 2016; 39: 63–72
- Puzanowska-Tarasiewicz H., Starczewska B., Kuźmicka L.: Reaktywne formy tlenu. Bromat. Chem. Toksykol., 2008; 41: 1007–1015
- Raiszadeh F., Solati M., Etemadi A., Azizi F.: Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin. Endocrinol., 2004; 60: 75–80
- Rajkovic M.G., Rumora L., Barisic K.: The paraoxonase 1, 2 and 3 in humans. Biochem. Med., 2011; 21: 122–130
- Resch U., Helsel G., Tatzber F., Sinzinger H.: Antioxidant status in thyroid dysfunction. Clin. Chem. Lab. Med., 2002; 40: 1132–1134
- Rotondo Dottore G., Ionni I., Menconi F., Casini G., Sellari-Franceschini S., Nardi M., Vitti P., Marcocci C., Marinò M.: Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): A new frontier for GO treatment? J. Endocrinol. Invest., 2018; 41: 193–201
- Rotondo Dottore G., Ionni I., Menconi F., Casini G., Sellari-Franceschini S., Nardi M., Vitti P., Marcocci C., Marinò M.: Antioxidant effects of β-carotene, but not of retinol and Vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO). J. Endocrinol. Invest., 2018; 41: 815–820
- Rotondo Dottore G., Leo M., Casini G., Latrofa F., Cestari L., Sellari-Franceschini S., Nardi M., Vitti P., Marcocci C., Marinò M.: Antioxidant actions of selenium in orbital fibroblasts: A basis for the effects of selenium in Graves’ orbitopathy. Thyroid, 2017; 27: 271–278
- Russell D.J., Wagner L.H., Seiff S.R.: Tocilizumab as a steroid sparing agent for the treatment of Graves’ orbitopathy. Am. J. Ophthalmol. Case Rep., 2017; 7: 146–148
- Sadani G.R., Nadkarni G.D.: Role of tissue antioxidant defence in thyroid cancers. Cancer Lett., 1996; 109: 231–235
- Salvi M., Vannucchi G., Currò N., Campi I., Covelli D., Dazzi D., Simonetta S., Guastella C., Pignataro L., Avignone S, Beck-Peccoz P.: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study. J. Clin. Endocrinol. Metab., 2015; 100: 422–431
- Sato A., Shirota T., Shinoda T., Komiya I., Aizawa T., Takemura Y., Yamada T.: Hyperuricemia in patients with hyperthyroidism due to Graves’ disease. Metabolism, 1995; 44: 207–211
- Schomburg L., Köhrle J.: On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol. Nutr. Food Res., 2008; 52: 1235–1246
- Seven A., Taşan E., Inci F., Hatemi H., Burçak G.: Biochemical evaluation of oxidative stress in propylthiouracil treated hyperthyroid patients. Effects of vitamin C supplementation. Clin. Chem. Lab. Med., 1998; 36: 767–770
- Shuai M., Ni Y., Jian X., He S., Zhang J.A.: The level of IL-35 in the circulation of patients with Graves’ disease. Endokrynol. Pol., 2019; 70: 318–322
- Smith T.J., Hegedüs L., Douglas R.S.: Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best. Pract. Res. Clin. Endocrinol. Metab., 2012; 26: 291–302
- Stuss M., Michalska-Kasiczak M., Sewerynek E.: The role of selenium in thyroid gland pathophysiology. Endokrynol. Pol., 2017; 68: 440–465
- Sugawara M., Kita T., Lee E.D., Takamatsu J., Hagen G.A., Kuma K., Medeiros-Neto G.A.: Deficiency of thyroid superoxide dismutase in endemic goiter tissue. J. Clin. Endocrinol. Metab.,1988; 67: 1156– 1161
- Świerkot M., Kulawik G., Sarnat-Kucharczyk M., Jagoda K., Mrukwa-Kominek E., Chudek J.: Long-term remission of steroid-resistant Graves’ orbitopathy after administration of anti-thymocyte globulin. Endokrynol. Pol., 2020; 71: 198–199
- Tanda M.L., Piantanida E., Liparulo L., Veronesi G., Lai A., Sassi L., Pariani N., Gallo D., Azzolini C., Ferrario M., Bartalena L.: Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J. Clin. Endocrinol. Metab., 2013; 98: 1443–1449
- Tang X.L., Liu X.J., Sun W.M., Zhao J., Zheng R.L.: Oxidative stress in Graves’ disease patients and antioxidant protection against lymphocytes DNA damage in vitro. Pharmazie, 2005; 60: 696–700
- Tsai C.C., Cheng C.Y., Liu C.Y., Kao S.C., Kau H.C., Hsu W.M., Wei Y.H.: Oxidative stress in patients with Graves’ ophthalmopathy: Relationship between oxidative DNA damage and clinical evolution. Eye, 2009; 23: 1725–1730
- Tsai C.C., Kao S.C., Cheng C.Y., Kau H.C., Hsu W.M., Lee C.F., Wei Y.H.: Oxidative stress change by systemic corticosteroid treatment among patients having active Graves’ ophthalmopathy. Arch. Ophthalmol., 2007; 125: 1652–1656
- Tsai C.C., Wu S.B., Cheng C.Y., Kao S.C., Kau H.C., Chiou S.H., Hsu W.M., Wei Y.H.: Increased oxidative DNA damage, lipid peroxidation and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ ophthalmopathy: Evidence that oxidative stress has a role in this disorder. Eye, 2010; 24: 1520–1525
- Tsai C.C., Wu S.B., Cheng C.Y., Kao S.C., Kau H.C., Lee S.M., Wei Y.H.: Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts. Mol. Vis., 2011; 17: 2782–2788
- Venditti P., Di Meo S.: Thyroid hormone-induced oxidative stress. Cell. Mol. Life Sci., 2006; 63: 414–434
- Veneskoski M., Turunen S.P., Kummu O., Nissinen A., Rannikko S., Levonen A.L., Hörkkö S.: Specific recognition of malondialde-hyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a. Free Radic. Biol. Med., 2011; 51: 834–843
- Von Basedow C.A.: Exophthalmos durch Hypertrophie des Zellgewebes in der Augenhöhle. Wochenschr. für die ges. Heilkunde,1840; 13: 197
- Wall J.R., Lahooti H.: Pathogenesis of thyroid eye disease – does autoimmunity against the TSH receptor explain all cases? Endokrynol. Pol., 2010; 61: 222–227
- Yavuz D.G., Yüksel M., Deyneli O., Ozen Y., Aydin H., Akalin S.: Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients. Clin. Endocrinol., 2004; 61: 515–521
- Yoon J.S., Lee H.J., Chae M.K., Lee S.Y., Lee E.J.: Cigarette smoke extract-induced adipogenesis in Graves’ orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress. J. Endocrinol., 2013; 216: 145–156
- Yuksel N., Yaman D., Pasaoglu O.T., Pasaoglu H.: The effect of smoking on mitochondrial biogenesis in patients with Graves’ ophthalmopathy. Ophthalmic. Plast. Reconstr. Surg., 2020; 36: 172–177
- Zafarullah M., Li W.Q., Sylvester J., Ahmad M.: Molecular mechanisms of N-acetyl-cysteine actions. Cell. Mol. Life Sci., 2003; 60: 6–20
DOI: https://doi.org/10.5604/01.3001.0014.9482 | Journal eISSN: 1732-2693
Language: English
Page range: 448 - 455
Submitted on: May 1, 2019
Accepted on: Aug 13, 2020
Published on: Jun 18, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Magdalena Londzin-Olesik, Beata Kos-Kudła, Aleksandra Nowak, Mariusz Nowak, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.